Latest CCO News

The Calmer Co has posted a record $2.01 million in sales for Q2 FY26, propelled by a 9% increase in US revenue which now accounts for over half of the group’s total income. Strong retail and wholesale growth underpin the company’s expanding footprint in the natural relaxation market.

The Calmer Co. International Limited has reported a second consecutive quarter of revenue exceeding $2 million, driven by strong U.S. growth and record monthly sales in December. The company’s strategic focus on wholesale and B2B extract channels underpins its confidence in reaching breakeven this fiscal year.

A few stocks did the heavy lifting this week, with one biotech exploding higher and a gas name collapsing on the other side of the ledger. Big moves came from capital raises, regulator decisions, and drill results that investors treated as near-term value, not distant promises.

The Calmer Co. International Limited has reported its highest ever monthly sales of $910,767 in December 2025, driven by strong wholesale growth and expanding US market presence.

The FDA’s recent ruling classifying traditionally prepared kava beverages as food under U.S. law clears a major regulatory hurdle for The Calmer Co, accelerating its growth on Amazon and strengthening its U.S. expansion strategy.

The Calmer Co. International Limited has completed a $1.4 million convertible note raise, positioning itself to accelerate wholesale growth and inventory build ahead of 2026.

The Calmer Co. International Limited announces a leadership change with James S. Tonkin appointed Chairman as the company accelerates its U.S. market growth in natural kava products.

The Calmer Co has reported a robust 26% increase in quarterly sales, driven by strong growth in Australia and the US, alongside a significant 39% reduction in cash used in operations, signaling clear progress toward profitability.

The Calmer Co. International Limited has delivered its strongest quarter yet, with revenue surging 26% to $2.4 million and operating cash outflows dropping to a historic low. Strategic growth across retail, e-commerce, and B2B channels underpins its confident path to breakeven.

The Calmer Co (ASX – CCO) reported an impressive $8 million revenue for FY25, marking 86% year-over-year growth and positioning itself as a global leader in the emerging kava market. With expanding retail presence and strong US sales, the company is on track to break even in 2026.

The Calmer Co International Limited has reported its strongest quarterly revenue ever at $2.4 million, driven by robust Australian retail sales and expanding US market presence. The company is also advancing a $1.4 million convertible note to fuel growth and inventory expansion.

The Calmer Co. has secured $700,000 in the first tranche of a $1.4 million convertible note raise, welcoming US distributor Applied Food Sciences as a strategic investor to fuel its expanding wholesale presence.